- Home
- BL vs TYRA Comparison
BL vs TYRA Comparison
Compare BL & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BL | TYRA |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BL | TYRA |
|---|---|---|
| Price | $29.33 | $35.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 11 |
| Target Price | ★ $56.62 | $47.50 |
| AVG Volume (30 Days) | 1.0M | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $177,031,000.00 | N/A |
| Revenue This Year | $12.62 | N/A |
| Revenue Next Year | $10.90 | N/A |
| P/E Ratio | $75.33 | ★ N/A |
| Revenue Growth | ★ 43.78 | N/A |
| 52 Week Low | $28.78 | $8.75 |
| 52 Week High | $59.57 | $40.65 |
Technical Indicators
Market Signals| Indicator | BL | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 29.82 | 48.74 |
| Support Level | N/A | $34.01 |
| Resistance Level | $58.85 | $39.90 |
| Average True Range (ATR) | 1.67 | 1.85 |
| MACD | -0.19 | -0.13 |
| Stochastic Oscillator | 3.63 | 37.13 |
Price Performance
Historical ComparisonAbout BL BlackLine Inc.
BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their critical processes, including financial close & consolidation, intercompany accounting, and invoice-to-cash. The majority of the revenue of the company is earned in the United States.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.